Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study

Maaike J Vos, Tjeerd J Postma, Frans Martens, Bernard M J Uitdehaag, Marines A Blankenstein, W Peter Vandertop, Ben J Slotman, Jan J Heimans

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting.

PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" (< or = median value) serum S-100B and NSE levels.

RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups.

CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.

Original languageEnglish
Pages (from-to)2511-4
Number of pages4
JournalAnticancer Research
Volume24
Issue number4
Publication statusPublished - 28 Aug 2004

Cite this

@article{0ce11451d8c34f45a104075399c073af,
title = "Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study",
abstract = "BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting.PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with {"}high{"} (> median value) versus {"}low{"} (< or = median value) serum S-100B and NSE levels.RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups.CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.",
keywords = "Adult, Brain Neoplasms/blood, Female, Glioma/blood, Humans, Male, Middle Aged, Nerve Growth Factors, Phosphopyruvate Hydratase/blood, Pilot Projects, Prognosis, S100 Calcium Binding Protein beta Subunit, S100 Proteins/blood",
author = "Vos, {Maaike J} and Postma, {Tjeerd J} and Frans Martens and Uitdehaag, {Bernard M J} and Blankenstein, {Marines A} and Vandertop, {W Peter} and Slotman, {Ben J} and Heimans, {Jan J}",
year = "2004",
month = "8",
day = "28",
language = "English",
volume = "24",
pages = "2511--4",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

Serum levels of S-100B protein and neuron-specific enolase in glioma patients : a pilot study. / Vos, Maaike J; Postma, Tjeerd J; Martens, Frans; Uitdehaag, Bernard M J; Blankenstein, Marines A; Vandertop, W Peter; Slotman, Ben J; Heimans, Jan J.

In: Anticancer Research, Vol. 24, No. 4, 28.08.2004, p. 2511-4.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Serum levels of S-100B protein and neuron-specific enolase in glioma patients

T2 - a pilot study

AU - Vos, Maaike J

AU - Postma, Tjeerd J

AU - Martens, Frans

AU - Uitdehaag, Bernard M J

AU - Blankenstein, Marines A

AU - Vandertop, W Peter

AU - Slotman, Ben J

AU - Heimans, Jan J

PY - 2004/8/28

Y1 - 2004/8/28

N2 - BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting.PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" (< or = median value) serum S-100B and NSE levels.RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups.CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.

AB - BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting.PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" (< or = median value) serum S-100B and NSE levels.RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups.CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.

KW - Adult

KW - Brain Neoplasms/blood

KW - Female

KW - Glioma/blood

KW - Humans

KW - Male

KW - Middle Aged

KW - Nerve Growth Factors

KW - Phosphopyruvate Hydratase/blood

KW - Pilot Projects

KW - Prognosis

KW - S100 Calcium Binding Protein beta Subunit

KW - S100 Proteins/blood

M3 - Article

VL - 24

SP - 2511

EP - 2514

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -